1-10 of 10
Virginia Dalton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Omar Nadeem, Robert A. Redd, Peter Barth, Clifton C Mo, Jacob P. Laubach, Giada Bianchi, Trevor J. Bayliss, Vaishali Sanchorawala, Leyla Shune, Alexandra Distaso, Virginia Dalton, Mary McKenney, Sarah Patches, Isabella Hou, Lindsay Issokson, Anna Barrell, Kelly Masone, Adam S. Sperling, Nikhil C. Munshi, Irene M. Ghobrial, Kenneth C. Anderson, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 1650.
https://doi.org/10.1182/blood-2021-146866
Published: 2021
Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Omar Nadeem, MD, Clifton C Mo, MD, Jacob P. Laubach, MD, Giada Bianchi, MD, Robert Redd, Peter Barth, Trevor J. Bayliss, MD, Vaishali Sanchorawala, MD, Leyla Shune, MD, Alexandra Distaso, Virginia Dalton, MS, APRN, Adam S Sperling, MD PhD, Laura Amweg, Mary McKenney, NP, Kathleen Colson, BS,BSN,RN, Ella L Millard, Isabella Hou, Alexandra Savell, BS, Kelly Masone, BA, Nikhil C. Munshi, MD, Irene M. Ghobrial, MD, Kenneth Anderson, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-141549
Published: 2020
Journal Articles

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Shawn O. Streeter, PharmD, Omar Nadeem, MD, Paul G. Richardson, MD, Jacob P. Laubach, MD, Clifton C. Mo, MD, Kimberly Noonan, RN, NP, AOCN, Mary McKenney, NP, Tina Flaherty, ANP-BC, AOCN, Virginia Dalton, MS, APRN, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-143385
Published: 2020
Journal Articles

A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.

Jennifer R Brown, MD, PhD, Bradley Messmer, Lillian Werner, Evgeny Mikler, David C. Fisher, MD, Ann LaCasce, MD, MSc, Philippe Armand, MD, PhD, Eric D Jacobsen, MD, Virginia Dalton, Bethany Tesar, Stacey M Fernandes, Sean McDonough, MS, Jerome Ritz, MD, Laura Z Rassenti, PhD, Thomas J. Kipps, MD, PhD, Donna Neuberg, ScD, Arnold S. Freedman, MD
Journal: Blood
Blood (2010) 116 (21): 1381.
https://doi.org/10.1182/blood.V116.21.1381.1381
Published: 2010
Journal Articles

A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL.

Jennifer R Brown, MD, PhD, Jeremy S. Abramson, MD, Ephraim P. Hochberg, MD, Evgeny Mikler, Virginia Dalton, Hazel Reynolds, Jennifer Romano, Lillian Werner, MS, Christina Thompson, Sean McDonough, Jerome Ritz, MD, Donna Neuberg, ScD, Arnold S. Freedman, MD
Journal: Blood
Blood (2009) 114 (22): 3426.
https://doi.org/10.1182/blood.V114.22.3426.3426
Published: 2009
Journal Articles

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01

Jianbiao Zhou, Meredith A Goldwasser, Aihong Li, Suzanne E. Dahlberg, Donna Neuberg, Hongjun Wang, Virginia Dalton, Kathryn D McBride, Stephen E. Sallan, Lewis B Silverman, John G. Gribben
Journal: Blood
Blood (2007) 110 (5): 1607–1611.
https://doi.org/10.1182/blood-2006-09-045369
Published: 2007
Includes: Supplemental data
Journal Articles

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

Jonathan W. Friedberg, MD, MMSc, Jennifer Kelly, MPH, Jeffrey L. Kutok, MD, Rabih Salloum, MD, David C. Fisher, MD, Elizabeth Ronan, Virginia Dalton, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, MD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD
Journal: Blood
Blood (2006) 108 (11): 2713.
https://doi.org/10.1182/blood.V108.11.2713.2713
Published: 2006
Journal Articles

Quantitative Analysis of Minimal Residual Disease at the Completion of Induction Therapy Predicts Relapse in Children with B-Lineage Acute Lymphoblastic Leukemia in DFCI ALL Consortium Protocol 95-01.

Jianbiao Zhou, MD MSc, Aihong Li, MD PhD, Meredith A. Goldwasser, ScD, Hongjun Wang, BS, Virginia Dalton, RN, Cheryl Lyons, BS, Kathryn D. McBride, MPH, Stephen E. Sallan, MD, Lewis B. Silverman, MD, John G. Gribben, MD DSc
Journal: Blood
Blood (2004) 104 (11): 323.
https://doi.org/10.1182/blood.V104.11.323.323
Published: 2004
Journal Articles

Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis

Clinical Trials & Observations
Aihong Li, Montse Rue, Jianbiao Zhou, Hongjun Wang, Meredith A. Goldwasser, Donna Neuberg, Virginia Dalton, David Zuckerman, Cheryl Lyons, Lewis B. Silverman, Stephen E. Sallan, John G. Gribben, for the Dana-Farber Cancer Institute ALL Consortium
Journal: Blood
Blood (2004) 103 (12): 4602–4609.
https://doi.org/10.1182/blood-2003-11-3857
Published: 2004
Journal Articles

Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection

Clinical Trials & Observations
Aihong Li, Jianbiao Zhou, David Zuckerman, Montse Rue, Virginia Dalton, Cheryl Lyons, Lewis B. Silverman, Stephen E. Sallan, John G. Gribben
Journal: Blood
Blood (2003) 102 (13): 4520–4526.
https://doi.org/10.1182/blood-2003-05-1455
Published: 2003